Hematology

Inotuzumab ozogamicin (Besponsa) granted FDA approval to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Understanding why some patients fail to respond to immunotherapy could improve treatments for cancer.

Bruce A. Feinberg, DO, Vice President and Chief Medical Officer of Cardinal Health Specialty Solutions, discusses the expanding role of educational patient support programs in oncology.

Anti-rheumatic drug suppresses activation of a molecular pathway responsible for the disease.

Brandon Shank, PharmD, MPH, BCOP, discusses the role of the oncology pharmacist in providing consultation and maintaining communication with cancer patients during treatment.

Vyxeos is a combination chemotherapy that treats a pair of high-risk subsets of acute myeloid leukemia.

Vyxeos is indicated to treat newly diagnosed therapy-related AML or AML with myelodysplasia-related changes.

Officials with the FDA have approved enasidenib (Idhifa, Celgene Corporation) to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation, isocitrate dehydrogenase-2 (IDH2), according to a FDA press release.

Gemtuzumab ozogamicin observed to benefit subset of patients with acute myeloid leukemia.

Novel drug may increase immune system attack against cancer cells in patients with myelodysplastic syndrome.

One-third of patients with myelodysplastic syndrome progress to acute myeloid leukemia.

The ClearLLAb Reagents test can detect cancer cells in the blood.

CTL019 is a chimeric antigen receptor T cell therapy.

Two KEYNOTE trials were placed on full clinical hold and 1 partial clinical hold.

Prembrolizumab (Keytruda) combination observed to have a high mortality rate.

Sandoz has the highest number of biosimilars approved in Europe.

CTL019 is an investigational chimeric antigen receptor T cell therapy.

Nilotinib (Tasigna) may lead to treatment-free remission among certain patients with chronic myeloid leukemia.

Data suggests favorable tolerability of novel treatment in patients with relapsed or refractory AML.

Top articles of the week from The American Journal of Pharmacy Benefits.

The approval is based on multiple clinical trials, and provides patients with a subcutaneous option for rituximab that shortens the treatment time to 5 to 7 minutes compared with intravenous infusion.

The cost of squamous cell cancer of the head and neck is driven primarily by the end-of-life phase. Treatment costs increased following the approval of cetuximab.

When making coverage decisions in oncology, payers find difficulties in translating evidence on treatment effect heterogeneity into coverage policies.

Alectinib found to reduce the risk of disease progression or death by more than 50% in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer.

CAR T-cell therapy shows significant progress towards a cure for multiple myeloma.

Advances in treatment and care improved the 5-year survival rate after diagnosis by 26%.

Ibrutinib (Imbruvica) may extend survival for patients with leukemia.

Ibrutinib (Imbruvica) may extend survival for patients with leukemia.

Top news of the week in oncology and cancer drug development.

An investigational device can detect and regulate drug levels in the blood.